Skip to search formSkip to main contentSkip to account menu

S49076

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 3924: Aurora B, a potential new target in non-T790M lung cancer cells with acquired resistance to anti-EGFR therapy, is effectively blocked by the MET/AXL/FGFR inhibitor S49076
2017
2017
MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
2016
2016
Abstract 321: S49076, a novel kinase inhibitor of MET, AXL and FGFR, demonstrates marked in vitro and in vivo efficacy in hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) is the second cause of cancer-related deaths worldwide. While sorafenib may improve… 
2015
2015
Abstract 2568: S49076, a MET, AXL, FGFR inhibitor, potentiates radiation therapy in subcutaneous and orthotopic models of lung cancer
S49076 is an oral ATP-competitive inhibitor of the receptor tyrosine kinases MET, AXL, and FGFR1-3 currently in phase I/II… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)